

Lupin launches generic solution of pneumonia in US

13 November 2018 | News

Lupin's Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC's Mepron oral suspension 750 mg/5 mL.



Pharma major Lupin has announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC's Mepron® oral suspension 750 mg/5 mL. It is indicated for the prevention of *Pneumocystis jirovecii* pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately \$119 million in the US (IQVIA MAT September 2018).